Performance Enhancing Drugs Abuse

Running head: PERFORMANCE ENHANCING DRUGS ABUSE
Performance Enhancing Drugs Abuse
Student’s name:
University:

1
PERFORMANCE ENHANCING DRUGS ABUSE
Executive summary:
The following paper discusses and analyses the phenomenon of performance enhancing drug
abuse in the context of the scandalous doping controversy of Tour de France winner cyclist
Lance Armstrong. The discussion describes the incident with a brief definition of PEDs. It then
focuses on the drugs and substances used by Armstrong and discusses their mechanism, benefits
and perceived side effects. Further, it describes the legal proceedings against Armstrong and
their consequences on his career. It concludes with the impact of the incident on Armstrong’s
personal life as well as the athletic fraternity at large.

2
PERFORMANCE ENHANCING DRUGS ABUSE
Table of Contents
Introduction................................................................................................................................3
Lance Armstrong scandal...........................................................................................................3
PEDs used by Armstrong and their side effects.........................................................................3
Erythropoietin or EPO........................................................................................................3
Dieuretics...........................................................................................................................4
Human Growth Hormones or somatotropin.......................................................................4
Armstrong’s perception of the issue..........................................................................................5
Investigation and consequences.................................................................................................5
Conclusion..................................................................................................................................5
References..................................................................................................................................6